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ABSTRACT 
 
SYNTHESIS AND CHARACTERIZATION OF TIME-RESOLVED FLUORESCENCE 
PROBES FOR THE POTENTIAL DETECTION AND IMPROVED STUDY OF MELANOMA 
CANCER 
Seth Alexander Sedberry 
Western Carolina University (August, 2016) 
Director: Dr. Carmen Huffman 
 
A multi-part fluorescent probe was designed for the development of new clinical tools for the 
detection and treatment of melanoma skin cancer.  It has been proposed that the addition of a 
fluorescent tag to a melanocyte stimulating hormone1 would create a luminescent probe with 
potential for the detection and study of melanoma skin cancer.  The proposed design involves 
attaching a luminescent lanthanide probe to an MSH (4) peptide substrate using a flexible 
polyethylene glycol linker.  The individual portions of the proposed molecule (luminescent 
probe, PEGO linker, and MSH (4) peptide) have been synthesized and characterized using a 
combination of FTIR, NMR, GCMS, HPLC, UV-Vis, and Fluorescent spectroscopy. 
Luminescent probe synthesis involved the nitration and subsequent reduction of 1,10-
phenanthroline followed by complexation with Eu(TTA)3.  Synthesis of the PEGO linker was 
accomplished by the reaction of tetraethylene glycol with tert-butyl bromoacetate to form a 
diacid through a t-butyl protected intermediate.  MSH (4) peptide synthesis proceeded on solid 
phase following a f-moc protocol and using a Mars6 microwave synthesizer.  Future work will 
focus on the construction of the final molecule using the components obtained herein.    
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CHAPTER 1: INTRODUCTION 
 
1.1 PROBLEM STATEMENT 
Traditional forms of biological imaging suffer from various limitations that inhibit their use 
in medical applications.  Limitations such as the presence of the background signal generated by 
the analyte's environment limit the sensitivity and dynamic range of the observation.  Traditional 
chromophores make use of UV light to excite the luminophore, which damages the biological 
sample and is not ideal2.  Other methods such as the use of chemical dyes exhibit photo-
bleaching and poor chemical stability, which are disadvantageous.  One way to overcome these 
obstacles is through the use of Eu3+ labels.  Europium (III) luminophores are advantageous over 
traditional luminophores because of their long luminescent lifetimes and narrow emission bands, 
which in turn delivers greater assay sensitivity while also being capable of excitement in 
presence of visible light3.  These properties make Eu3+ a prime target for use in the development 
of clinical tools for biological imaging.  
1.2 BACKGROUND 
1.2.1 MALIGNANT MELANOMA AND G-PROTEIN COUPLED RECEPTORS 
Cutaneous melanoma is a type of skin cancer that develops from pigment containing cells 
known as melanocytes, which in just 2012 occurred in 232,000 people and resulted in 55,000 
deaths making it the most dangerous form of skin cancer4.  The primary cause of melanoma skin 
cancer is exposure to UV light, generally from the sun or from tanning beds, which damages 
DNA in the skin.  The damaged DNA emits a signal received by melanocytes, found between the 
dermal and epidermal layer of the skin, causing the production of melanin(Fig. 1). 5   Melanin 
has a direct positive effect because of its ability to absorb the energy from UV light and convert 
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it into heat.  The earliest stage of melanoma begins with the uncontrolled, radial growth of the 
melanocytes6.  
 
Figure 1. Location of melanocyte and melanin production in the skin5. 
 
 During this radial growth phase, the tumor remains less than 1mm thick and has not 
reached the blood vessels deeper in the skin, making it unlikely to spread throughout the body at 
that time6.  If the tumor is detected during this phase, it can usually be completely removed with 
surgery. The development of melanoma is directly related to its ability to hijack the signaling 
mechanism that the body uses to protect skin DNA.  Therefore the study of the signaling 
pathways of melanocytes is of high importance to the development of new clinical tools for 
detection and treatment of melanoma.  
 Melanocyte signaling pathways involve the activation and deactivation of G-Protein 
Coupled Receptors (GPCR’s), which are the single largest family of cell-surface molecules 
involved in signal transmission and are present in just about every organ system.7  The receptor 
is a globular polypeptide embedded in a cell’s surface which binds to a signaling molecule, 
causing a conformational change and activating a G-Protein on the interior of the cell.  In this 
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way GPCR’s act like a switch, turning off or on through signal-receptor interactions on the cell’s 
surface7,8. (Fig.2) 
 
 
 
 
  
Figure. 2. A G-Protein Coupled Receptor activating a cell’s signaling pathway through the 
presence of an agonist (signaling molecule)8. 
 
This system is therefore regulated by the presence of a signaling molecule, which is in this 
instance a family of peptide hormones known collectively as melanocyte stimulating hormones 
(MSH).  This family consists of an alpha, a beta, and a gamma hormone which are produced by 
cells in the intermediate lobe of the pituitary gland1.  These short peptides all share the conserved 
His-Phe-Arg-Trp amino acid sequence (Table 1). 
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α-MSH: Ac-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val 
β-MSH (human): 
Ala-Glu-Lys-Lys-Asp-Glu-Gly-Pro-Tyr-Arg-Met-Glu-His-Phe-
Arg-Trp-Gly-Ser-Pro-Pro-Lys-Asp 
β-MSH (porcine): 
Asp-Glu-Gly-Pro-Tyr-Lys-Met-Glu-His-Phe-Arg-Trp-Gly-Ser-
Pro-Pro-Lys-Asp 
γ-MSH: Tyr-Val-Met-Gly-His-Phe-Arg-Trp-Asp-Arg-Phe-Gly  
 
Table 1. Table of Melanocyte Stimulating Hormone Variations 
 
These hormones (primarily α -MSH) bind with GPCR’s to signal the production of melanin 
in the skin.  Because of this ability to bind with the cell surface of the melanocyte, MSH peptides 
are good targets for the development of clinical tools for the imaging, detection, and study of 
melanoma skin cancer1.  We have proposed that using a MSH peptide as a foundation, a 
luminescent lanthanide complex could be tethered to the hormone using a polyethylene glycol 
linker in an attempt to make a biologically active fluorescent tag for the study of the melanocyte 
signaling pathway.   
1.2.2 LANTHANIDE AND LIGAND CHEMISTRY 
 Lanthanide complexes exhibit properties such as having narrow emission bands and a 
long luminescent lifetime.  These properties make them favorable candidates for possible bio-
imaging agents.  The lanthanide (III) ion’s narrow emission bands are due to the shielding of the 
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4f orbitals by the filled 5s and 5p sub-shells.9 However direct excitation of f-electrons from 
lanthanide (III) is difficult.  This is because of the forbidden nature of 4f-4f electronic transitions 
due to their orbital parity being the same in both the initial and final states (Laporte forbidden).10  
Selection rules dictate that excitement of the lanthanide (III) ion must occur during a temporary 
change in geometric arrangement around the ion or mixing with opposite parity wave functions 
from 5d orbitals, ligand orbitals, or charge transfer states3.  Because of the low probability of an 
electric dipole f-f transition and direct excitation of the lanthanide is difficult.  As a result an 
organic chromophore ligand is required to transfer energy to the lanthanide (III) ion and induce 
luminescence.  The organic ligand forms a chelate with the lanthanide and transfers absorbed 
energy to the luminophore through a process described as “the antenna effect” (Fig. 3).3  
 
 
Figure 3. The “Antenna Effect”2 
Through intersystem crossing, the excited electrons inhabit the triplet state of the ligand and can 
then transfer energy from the triplet state to the emissive state of the lanthanide complex center9. 
To maximize efficiency, the antenna ligand needs to have a triplet state (T1) energy that is  close 
to the energy of the lanthanide (III) ion to achieve the energy transfer necessary for emission10.  
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Figure 4. Visualization of a Stoke’s Shift12 
 
 Europium (III) complexes are specifically advantageous over other lanthanide complexes 
because they can be sensitized with visible, longer wavelength light as opposed to shorter 
wavelength UV excitation and is less harmful to biological targets, which is a primary objective 
in the development of clinical tools.  Additional advantages of Europium complexes include a 
narrow emission line in the red light region and a long luminescent lifetime which guarantees 
minimal interference from fluorescing biological samples11.  This as well as a large Stokes shift 
and a high quantum yield make Eu3+ a prime target for coordination with organic chromophore 
ligands used in biological imaging applications 2,12. (Fig. 4) 
1.3 OBJECTIVES 
 The proposed molecule can be split up into three distinct components: a fluorescent 
lanthanide complex, a polyethylene glycol linker, and a melanocyte stimulating hormone     
(MSH (4)).  (Fig. 5) 
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Figure 5. Three component design of the proposed molecule. 
The melanocyte stimulating hormone is a peptide produced by the pituitary gland and 
functions to bind with the G-protein coupled receptor found in the cell membrane of the 
melanocyte that is up-regulated in melanoma cancer cells.  Attached to the MSH (4)-PG peptide 
(10) is a luminescent lanthanide complex (6).  This lanthanide chelate tag is composed of a 
phenanthroline chromophore (2) which acts to absorb light and transfer it to the lanthanide metal, 
the emission of which can be used to detect the molecule.  Tethering the peptide and lanthanide 
chelate is a polyethylene glycol linker (8) that both tethers the two together while ensuring that 
the two remain far enough apart to allow for proper binding of the peptide at the melanocyte’s g-
protein coupled receptors.  Goals of this research project include: synthesis of an organic 
phenanthroline chromophore (2), synthesis of a polyethylene glycol linker (8), synthesis of a 
melanocyte stimulating hormone peptide (10), final assembly of the three previously listed 
components on a solid phase resin, cleavage from the solid phase resin, and final formation of 
the luminescent lanthanide complex.  The completed molecule should then be able to function as 
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a biologically active luminescent tag with the potential for use as a clinical tool to detect and 
study melanoma skin cancer. 
 Synthesis of an organic phenanthroline chromophore was first achieved.  The 5-Amino-
1,10-phenanthroline (2) was synthesized from 1,10-phenanthroline through a nitration reaction 
followed by a reduction of the attached nitro group12 (Scheme 1).  Firstly fuming nitric acid was 
added to a refluxing solution of 1,10-phenanthroline in sulfuric acid  to yield 5-nitro-1,10-
phenanthroline (1).  5-Nitro-1,10-phenanthroline (1) was then reduced to 5-amino-1,10-
phenanthroline (2) using hydrazine and a palladium catalyst to form a ligand with an amine 
functional group for the attachment of the  PEGO linker.  These compounds were characterized 
by FT-IR, GCMS, and NMR. 
      
 
 
1                 2 
Scheme 1.  The synthesis of 5-Amino-1,10-Phenanthroline involves the reduction of 5-Nitro-
1,10-Phenanthroline from the nitrated 1,10-Phenanthroline in 64% and 84% yield respectively. 
 
The three ligands were then complexed with a previously synthesized Eu(TTA)3-2H2O (3) 
molecule to form functional luminescent molecules, which were characterized using a 
combination of UV-Vis and fluorescent spectroscopy to form a qualitative luminescent profile of 
the molecules (Scheme 2). Analysis revealed an absorbance max of ~340 nm and a strong 
emission at ~615 nm.  
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Scheme 2. Complexation involves the reaction of EuCl3 6H20 with TTA to form Eu(TTA)3-
2H2O in31% yield.  This was reacted with a phenanthroline ligand to form a luminescent tag. 
  
To achieve attachment of the luminescent tag with the binding peptide, a linker must be used 
that fulfills two requirements: it must remain soluble while also maintaining enough distance 
between to allow the peptide to allow proper binding to the receptor.  Accordingly, a modified 
polyethylene glycol diacid (8) was chosen for the proposed linker due to its ability to bond with 
amine groups while maintaining solubility.  Linker synthesis was accomplished by combining 
tetraethylene glycol and tert-butyl bromoacetate in a solution of sodium hydride and THF.13  The 
resulting t-butyl protected PEGO (7) structure was next reacted in formic acid to yield the 
deprotected PEGO (8) structure capable of replicating the C-terminus end of a peptide structure 
rendering it able to couple with amines (Scheme 3). 14  Compounds were analyzed using a 
combination FT-IR, GCMS, HPLC and NMR to confirm successful synthesis. 
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Scheme 3.  Synthesis of the modified PEGO (7) linker involves the nucleophilic addition of tert-
butyl bromoacetate to tetra ethylene glycol occurred in 82% yield. Deprotection with fromic acid 
produced the deprotected PEG linker 8 in quantitative yield.  This molecule will attach the 
luminescent tag to the binding peptide. 
 
The third portion of synthesis regarded the microwave assisted solid phase synthesis of the 
MSH (4)-PG peptide (10). The MSH (4) peptide was chosen for its ability to bind with 
melanocyte surface receptors. A proline-glycine residue was added to the peptide to increase 
distance between the ligand and the binding site in an effort to increase affinity. The peptide was 
synthesized on a rink amide resin with assistance from a Mars6 microwave synthesizer.  
Completed peptide was analyzed using LCMS and HPLC to reveal purity of greater than 90% at 
the target mass.  
 
 
7 
8 
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Figure 6. MSH (4) –PG (His-Phe-Arg-Trp-Pro-Gly)   
 
Thesis research concluded with an attempt to complete the final molecule. The reaction protocol 
attempted to first attach one terminus of the PEGO linker to the phenanthroline ligand, with the 
second terminus remaining a carboxylic acid. This was proposed in an effort to prevent cross 
coupling of the PEGO linker with the peptide substrate. The reaction protocol next called for the 
attachment of the newly formed linker-ligand molecule to the peptide on solid phase to form the 
proposed peptide-linker-ligand compound. Once obtained, this molecule could then be cleaved 
from the resin and mixed in solution with Eu(TTA)3-2H2O to form  a luminescent chelate- 
completing synthesis of the target molecule.  
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CHAPTER 2: EXPERIMENTAL 
 
All reagents were purchased from Sigma Aldrich or Acros Organics and used without 
further purification unless otherwise stated. Synthesized ligands and complexes were characterized 
using Fourier-transform infrared spectroscopy (FT-IR), nuclear magnetic resonance (NMR, when 
applicable), UV-visible and fluorescence spectroscopic techniques, high pressure liquid 
chromatography (HPLC), gas chromatography (GC), and mass spectroscopy (GCMS, LCMS).  
The methods used for characterization will be discussed in this section along with all instrument 
specifications. 
2.1 MATERIALS AND INSTRUMENTATION 
2.1.1 FTIR 
FT-IR spectra were obtained using a Perkin Elmer Spectrum One. All measurements 
were performed at room temperature with a scanning range of 4000 cm-1 – 600 cm-1, using single-
bounce attenuated total reflectance with a diamond crystal.  For all of the materials that were 
measured as a solid powder (all solvents had been removed), the background was performed on 
the instrument room environment.  The ATR plate was cleaned with a Kimwipe and acetone 
between each measurement. 
2.1.2 NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY (NMR) 
 NMR spectra were obtained using a JEOL 300 MHz Eclipse NMR with a 5 mm probe 
capable of detecting 1H and 13C nuclei.  Proton NMR samples were prepared using ~10 mg of 
material, in either deuterated chloroform (CDCl3) or deuterated dimethyl sulfoxide (d6-DMSO) 
unless otherwise stated, and spectra were obtained using a varying number of scans ranging from 
16-128 as to ensure an adequate signal-to-noise ratio was acquired.  13C NMR samples were 
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prepared similarly, except material was added until the deuterated solution became saturated. 
2.1.3 UV-VISIBLE ABSORPTION SPECTROSCOPY 
 UV-Vis spectra were collected using an Agilent 8453 UV-Vis spectrometer at room 
temperature. This instrument has two different sources: a deuterium lamp (for UV measurements), 
and a tungsten lamp (for visible measurements).  The use of a photodiode array detector allows 
the spectrometer to detect a wavelength range of 190 nm – 1100 nm at 1 nm intervals.  All of the 
blank and sample measurements were made using a quartz cuvette (1 cm path length).  
2.1.4 FLUORESCENCE SPECTROSCOPY 
Fluorescence spectra were acquired using a Perkin Elmer LS-55 Luminescence 
Spectrometer at room temperature.  The same solvent systems for the blanks (to correct for any 
solvent fluorescence), samples and references that were used for UV-Vis measurements were 
also used for fluorescence measurements.  A quartz cuvette was used for all measurements. A 
scanning range of 200 nm – 800 nm with a scan speed of 200 nm/min was used, with an 
excitation and emission slit of 5.0 nm.  Detection was accomplished a delay time of up to 400 μs 
following 340 nm excitation. 
2.1.5 GAS CHOMATOGRAPHY 
 Gas chromatograms were obtained using an Agilent Technologies 7890 A GC System with 
a 7693 Autosampler, a 5975 C Inert XL EI/CI MSD (with Triple Axis Detector), and an Agilent 
J&W GC Column-HP-5MS (30 m × 0.25 mm × 0.25 µm) using a split inlet.  Flow rate: 1.2mL/min, 
APC-3 pressure: 1.0, Inlet Temperature: 250oC, Oven Temperature: 80oC, MS Quad Temperature: 
150oC, MS Source Temperature: 230oC.  
2.1.6 LIQUID CHROMATOGRAPHY 
 High pressure liquid chromatography was performed using an Agilent Technologies 1220 
Infinity LC with a 99301 Prevail Select C18 column (L: 250 mm, ID: 4.6 mm) and a UV-Vis 
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1
N
N
H2SO4
HNO 3
detector. Mobile phase: A: 10% CH3CN B: 90% H2O, Flow Rate: 1.5mL/min, Column 
Temperature: 25oC, Detection: 214nm/280nm. LCMS was performed off site.  
 
2.2 FUNCTIONALIZED PHENANTHROLINE LIGAND AND EU3+ COMPLEX SYNTHESIS  
2.2.1 SYNTHESIS OF 5-NITRO-1,10-PHENANTHROLINE 
 
 
 
 
Scheme 4. Synthesis of 5-Nitro-1, 10-Phenanthroline 
 
5-Nitro-1,10-Phenanthroline (1). 1,10-phenanthroline (2.5g, 12.611 mmol, 1.0 eqv) was 
dissolved in Sulfuric acid (7.5 ml, 0.473 mol, 37.5 eqv) and heated to 160o C while stirring.  
Nitric acid (15 ml, 0.189 mol, 15 eqv) was added drop wise to the mixture and the resulting 
solution was stirred at 160 o C for 3 hours.  Upon addition of HNO3 the reaction violently 
evolved brown gas and refluxed.  The resulting clear-orange solution was then brought to room 
temperature and adjusted to a pH of 3 with a 3M solution of NaOH.  The yellow solid precipitant 
was then filtered and dried to yield 5-nitro-1,10-phenanthroline (1) (1.805 g, 8.015 mmol, 63.5 % 
yield).  m.p. = 217-220 oC.   NMR(300MHz, CDCl3) δ 9.25 (2H, mult.), δ 8.935(1H, dd, J =  3 
Hz,9 Hz), δ 8.60 (1H, s), δ 8.360(1H, dd, J =  3 Hz, 9Hz), δ 7.74(2H, mult.). 13 C NMR (300 
MHz, CDCl3) δ = 153.4, 151.4, 147.5, 146.0, 144.1, 137.7, 132.3, 125.4, 125.3, 124.3, 124.2, 
120.8 ppm.   FTIR (ATR): 1516, 1503, 1344, 831, 804, 731 cm-1.          
  
15 
 
1,10- 5-Nitro-
2 
N
N
NO2 N
N
NH2N2H2
Pd/C
1 
     2.2.2 SYNTHESIS OF 5-AMINO-1,10-PHENANTHROLINE 
 
  
 
 
 
Scheme 5. Synthesis of 5-Amine-1, 10-Phenanthroline 
 
5-Amino-1,10-Phenanthroline (2). 5-Nitro-1,10-phenanthroline (1) (1.805g, 8.105 mmol, 1 eqv) 
was reacted in ethanol (30 ml) with hydrazine monohydrate (4.64 ml, 0.143 mol, 17.5 eqv) and a 
palladium on carbon catalyst (300 mg).  5-Nitro-1,10-phenanthroline (1) was first dissolved in 
ethanol , the palladium catalyst was added, and the solution was purged with argon.  Hydrazine 
monohydrate was then added drop-wise over 30 minutes via syringe and the reaction mixture 
was heated to 70oC for 10 hours.  The reaction gained a bronze tint as it lightly refluxed.  The 
reaction mixture was then filtered and the solvent was removed under vacuum to yield 5-amino-
1,10-phenanthroline (2) (1.318g, 6.75 mmol, 84.3%) as a dry, bright red solid. m.p. = 140-143oC 
NMR (300 MHz, DMSO) δ 9.06 (1H, d, J =  3Hz), δ 8.71 (2H, dd, J = 3 Hz, 9 Hz), δ 8.16 (1H, 
d, J = 9 Hz), δ 7.79 (1H, mult.), δ 7.58 (1H, mult.), δ 6.89 (1H, s).  13C NMR δ = 153.43, 151.35, 
137.74, 132.31, 125.38, 124.29, 124.20, 120.83, 77.42, 77.00, 76.57. FTIR (ATR): 3423, 3363, 
3221, 1638, 1587, 1377, 1291, 1046, 867, 786, 734, 656 cm-1. 
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2.2.3 SYNTHESIS OF EU(TTA)3-2H2O 
 
 
Scheme 6. Synthesis of Eu(TTA)3-2H2O 
 
Eu(TTA)3-2H2O(3) Europium chloride hexahydrate (0.2582 g, 1 mmol, 1 eqv)  was dissolved in 
10ml de-ionized H2O. In a second flask, NaOH (0.118 g, 3 mmol, 3 eqv) and 
theonyltrifluoroacetone (0.999 g, 4.5 mmol,4.5 eqv) was dissolved in 10ml de-ionized H2O at 
40oC.  The second solution of NaOH and TTA was then added drop wise to the first solution of 
europium chloride hexahydrate while stirring.  The combined solution was stirred at 50oC-55oC 
for 0.5 hours then stirred at room temperature for 2.5 hours.  The reaction solution was filtered to 
obtain a white precipitant which was then washed with 500ml de-ionized H2O and 3ml hexane 
to yield Eu(TTA)3-2H2O (3) (0.267 g, 0.312mmol, 31.2%).  
 
 
 
 
3 
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2.2.4 SYNTHESIS OF 1,10-PHENANTHROLINE-EU(TTA)3 COMPLEX 
 
 
Scheme 7. Synthesis of 1,10-Phenanthroline - Eu(TTA)3 
 
1,10-Phenanthroline - Eu(TTA)3 (4).1,10-phenanthroline (13.8mg, 0.07mmol, 1 eqv.) was 
dissolved in 10ml of methanol and stirred.  In a separate Erlenmeyer flask, Eu(TTA)3-2H2O(3) 
(60mg, 0.07mmol, 1 eqv.) was dissolved in 5ml CHCl3.  The Europium solution was then added 
drop wise to the stirring phenanthroline solution.  Afterward the reaction was stirred at room 
temperature for 24 hours and filtered to yield 1,10-phenanthroline - Eu(TTA)3(4) as a white 
precipitant. Product characterized via Uv-Vis and fluorescent spectroscopy.  
 
 
 
 
 
4 3 
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2.2.5 SYNTHESIS OF 5-NITRO-1,10-PHENANTHROLINE-EU(TTA)3 COMPLEX 
 
 
Scheme 8. Synthesis of 5-Nitro-1,10-Phenanthroline - Eu(TTA)3 
 
5-Nitro-1,10-Phenanthroline - Eu(TTA)3 (5). 5-Nitro-1,10-phenanthroline (1) (11.87 mg, 0.07 
mmol, 1 eqv.) was dissolved in 10ml of methanol and stirred. In a separate Erlenmeyer flask, 
Eu(TTA)3-2H2O(3) (60 mg, 0.07 mmol, 1.3 eqv.) was dissolved in 5ml CHCl3.  The Europium 
solution was then added drop wise to the stirring phenanthroline solution.  Afterward the reaction 
was stirred at room temperature for 24 hours and filtered to yield 5-nitro-1,10-phenanthroline - 
Eu(TTA)3 (5) as a yellow precipitant. Product characterized via Uv-Vis and fluorescent 
spectroscopy. 
  
5 3 
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2.2.6 SYNTHESIS OF 5-AMINO-1,10-PHENANTHROLINE-EU(TTA)3 COMPLEX 
 
 
Scheme 9. Synthesis of 5-Amine-1,10-Phenanthroline-Eu(TTA)3 
 
5-Amino-1,10-Phenanthroline - Eu(TTA)3 (6). 5-amino-1,10-phenanthroline (2) (13.7 mg, 0.07 
mmol, 1 eqv.) was dissolved in 10ml of methanol and stirred.  In a separate Erlenmeyer flask, 
Eu(TTA)3-2H2O (3) (60 mg, 0.07 mmol, 1 eqv.) was dissolved in 5ml CHCl3.  The Europium 
solution was then added drop wise to the stirring phenanthroline solution.  Afterward the reaction 
was stirred at room temperature for 24 hours and filtered to yield 5-amino-1,10-phenanthroline-
Eu(TTA)3 (5) as an orange precipitant. Product characterized via Uv-Vis and fluorescent 
spectroscopy. 
 
 
 
 
6 3 
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2.3 POLYETHYLENE GLYCOL LINKER SYNTHESIS 
2.3.1 SYNTHESIS OF TERT-BUTYL 17-HYDROXY-19,19-DIMETHYL-3,6,9,12,15,18-
HEXAOXAICOSANOATE  
 
 
 
Scheme 10. Synthesis of tert‐butyl 17‐hydroxy‐19,19‐dimethyl‐3,6,9,12,15,18‐
hexaoxaicosanoate 
 
Tert‐butyl 17‐hydroxy‐19,19‐dimethyl‐3,6,9,12,15,18‐hexaoxaicosanoate (7). Tetraethylene 
glycol (1.0 g, 0.89 ml, 5.14mmol, 1.0 eqv) was added slowly to a stirred solution of sodium 
hydride in 10ml of dry THF and stirred at room temperature for 2 hours.  Following this, Tert-
butyl bromoacetate (3.0 g, 2.28ml, 15.44mmol, 3 eqv) was dissolved in a separate 10ml solution 
of dry THF and the glycol solution was chilled in an ice bath.  The tert-butyl bromoacetate 
solution was then added drop wise to the chilled glycol solution.  The reaction was stirred at 0oC 
for 2 hours, then at room temperature for 10 hours.  Solvent was then removed under rotary 
evaporation; the remaining residue was dissolved with water and extracted with diethyl ether. 
The extract was dried over magnesium sulfate and the solvent was removed under rotary 
evaporation.  The remaining residue was then heated and stirred under vacuum to remove 
remaining starting material yielding tert‐butyl 17‐hydroxy‐19,19‐dimethyl‐ 3,6,9,12,15,18‐
hexaoxaicosanoate (7) as a viscous clear yellow oil (1.779 g, 4.204mmol, 81.79% yield).  GCMS 
analysis revealed that the sample was 93% pure as demonstrated by area under the curve.  NMR 
(300 MHz, CDCl3) δ 3.94 (4H, s), δ 3.60 (16H), δ 1.40 (18H, s). C13 NMR (300 MHz, CDCl3)    
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δ = 169.46, 81.25, 77.43, 77.00, 70.48, 70.36, 68.79, 27.88.                                                      
FTIR (ATR): 2979, 2870, 1747,1366, 1224, 1120, 945, 844, 746 cm-1.  GC/MS: m/z: [M+] 265.1, 
147, 103, 57 - C(CH3)3, 41. 
 
2.3.2 SYNTHESIS OF 2-HYDROXY-1λ³,4,7,10,13,16‐HEXAOXAOCTADEC‐1‐YN‐18‐OIC 
ACID 
 
 
Scheme 11. Synthesis of ‐hydroxy‐1λ³,4,7,10,13,16‐hexaoxaoctadec‐ 1‐yn‐18‐oic acid 
 
2‐hydroxy‐1λ³,4,7,10,13,16‐hexaoxaoctadec‐1‐yn‐18‐oic acid (8) . Tert‐butyl 17‐hydroxy‐19,19‐
dimethyl‐3,6,9,12,15,18‐hexaoxaicosanoate (7) (1 eqv) was dissolved in 5ml of formic acid and 
stirred at room temperature for 2 hours.  Solvent was then removed under rotary evaporation to 
yield 2‐hydroxy‐1λ³,4,7,10,13,16‐hexaoxaoctadec‐ 1‐yn‐18‐oic acid (8) as a clear-yellow fluid 
oil  (1.293g, 4.169mmol, 99% yield).  HPLC analysis revealed a purity of 92% as demonstrated 
by area under the curve. NMR (300 MHz, CDCl3) δ 10.24 (2H, s), δ 4.16 (4H, s), δ 3.70 (16H, 
multi.) C13 NMR (300 MHz, CDCl3) δ = 173.93, 77.60, 77.18, 76.76, 71.21, 70.61, 70.37, 68.69. 
FTIR (ATR): 2921, 2874, 1728, 1421, 1348, 1196, 1088, 946, 846, 670 cm-1. 
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2.3.3 SYNTHESIS OF 2-CHLORO‐1λ³,4,7,10,13,16‐HEXAOXAOCTADEC‐1‐YN‐18‐OYL 
CHLORIDE  
 
 
Scheme 12. Synthesis of 2‐chloro‐1λ³,4,7,10,13,16‐hexaoxaoctadec‐1‐yn‐18‐oyl chloride 
 
2‐chloro‐1λ³,4,7,10,13,16‐hexaoxaoctadec‐1‐yn‐18‐oyl chloride (9). 2‐hydroxy‐1λ³,4,7,10,13,16‐
hexaoxaoctadec‐1‐yn‐18‐oic acid (8) (1 eqv) and oxalyl chloride (4 eqv) were mixed in 80ml of 
benzene in a round bottom flask under argon and stirred at room temperature.  To the mixture, 4 
drops of DMF was added and the reaction mixture was stirred at room temperature for 6 hours.  
Oxalyl chloride and benzene were then removed under rotary evaporation to yield 2‐chloro‐
1λ³,4,7,10,13,16‐hexaoxaoctadec‐1‐yn‐18‐oyl chloride(9) as a brown resin.  The obtained 
product was verified on FT-IR and was used for subsequent synthesis without purification.  FTIR 
(ATR): 3125, 2921, 2874, 1806, 1454, 1408, 1356, 1119, 928, 742, 678 cm-1.  
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2.4 PEPTIDE SYNTHESIS  
2.4.1 SYNTHESIS OF MELANOCYTE STIMULATING HORMONE (4) - PG  
 
 
 
 
 
 
Figure 7. Melanocyte Stimulating Hormone (4) -PG (His-Phe-Arg-Trp-Pro-Gly) (9) 
 
Melanocyte Stimulating Hormone(4)-PG (9). Synthesis was performed on solid support in a 
Mars6 microwave synthesizer with fiber optic temperature sensor from CEM Corp.  
Approximately 1250mg (0.5mmol) of Fmoc-Gly-CLEAR-Amide Resin was placed in a 50mL 
fritted plastic reaction vessel and the resin was swelled in 50% DMF and 50% DCM for one 
hour.  The initial deprotection was performed with about 6mL of 20% piperidine in DMF for 30 
seconds at 70oC followed by 30 seconds at 75oC.  The resin was washed with DMF and a Kaiser 
test performed to confirm the presence of a primary amine.  A 3-fold excess of the first amino 
acid was dissolved in DMF along with a 5-fold excess of Oxyma pure (coupling reagent).  A 5-
fold excess of DIC was added to the amino acid mixture and then the entire volume was added to 
the resin. Coupling was performed for five minutes at 75oC.  Another Kaiser test was then 
performed to confirm completion of the coupling reaction.  The deprotection and coupling cycle 
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was repeated as necessary until all amino acids were added to the growing peptide chain.  After 
addition of the last amino acid the resin was washed with DCM, and stored at 4oC.  Due to the 
metal interior of the Mars6 microwave, cleavage of the peptide chain was performed on bench 
top. Approximately 6ml of cleavage cocktail (90% TFA/3% H2O/3% 1,2-ethandithiole/3% 
thioanisole) was added to the dried resin and cleavage was performed at room temperature for 6 
hours.  Cleaved peptide was collected by filtration, precipitated in cold ether, and centrifuged for 
30 minutes at 4o C.  The peptide was dissolved in water and lyophilized to a powder.  HPLC 
analysis revealed crude peptide purity as greater than 83% pure as demonstrated by area under 
the curve.  Peptide was analyzed for molecular weight by LC-MS with an M+1 mass spectral 
analysis within equipment error.  Initial results displayed an observed purity greater than 70% 
with an M+1 peak of 781, indicating the presence of a major peptide product at the desired mass. 
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RESULTS & DISCUSSION 
 The overarching goal of this project was to create a fluorescent tag for use in studying 
melanoma skin cancer.  A three part molecule was designed to study the hormone signaling 
pathway involved in malignant tumor growth.  The three combined portions of the proposed 
molecule included a fluorescent phenanthroline-europium complex, a polyethylene glycol linker, 
and a melanocyte-binding peptide.  The hypothesis was that this novel, three-part molecule 
would allow for the improved study and detection of melanoma skin cancer by creating a 
fluorescent lanthanide tag that does not interfere with the binding of the MSH (4) peptide by way 
of a modified polyethylene glycol linker, thus allowing the molecule to be taken up into the 
cancer cell and followed via fluorescent imagery.  Currently, the three individual components of 
the final molecule have been synthesized and characterized.  
3.1 PHENANTHROLINE LIGAND AND EU3+ COMPLEXES 
3.1.1 SYNTHESIS AND CHARACTERIZATION 
 
 
  
 
 
  
 Scheme 13. Synthesis of 5-Amine-1, 10-Phenanthroline 
 
 5-Nitro-1,10-phenanthroline (1) was synthesized by the nitration of 1,10-phenanthroline.   
This was accomplished by heating a HNO3/H2SO4 solution at 70
o C for at least 3 hours.12  Yield 
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of the reaction was sensitive to reaction time, temperature and work-up conditions.   A 
systematic study of these factors was not investigated.  Heating the reaction mixture at reflux 
seemed to produce lower yields.  However, the yield of the reaction seemed to improve with 
longer heating times.  Work-up involved pouring the reaction mixture over ice and adjusting to a 
pH of 3 using 6M NaOH.  Product precipitated as a yellow solid and was isolated by filtration.  
This was problematic and frequently resulted in no precipitate forming or the precipitation of 
large quantities of Na2SO4 as a white solid.  When this occurred, the Na2SO4 was removed by 
filtration and the filtrate extracted with CH2Cl2.  The reaction proceeded in adequate yields 
(63.5%) to produce a light yellow solid.  NMR spectra of 5-nitro-1,10-phenanthroline (1) 
displayed the required singlet at δ8.60 as well as 2 doublet of doublets and 2 multiplets which 
integrated to a total of 7 hydrogens, indicating successful synthesis of the target molecule.  FTIR 
spectra of 5-nitro-1,10-phenanthroline (1) showed the expected NO2 stretching bands.   
 5-Amino-1,10-phenanthroline (2) was obtained following the nitration of 1,10-
phenanthroline and the subsequent reduction of 5-nitro-1,10-phenanthroline (1).   Both of these 
reactions were followed by NMR.  The reaction proceeded smoothly and in good yields (84.3%).  
Reduction was accomplished using hydrazine and palladium on charcoal with ethanol as a 
solvent.  Ethanol was degassed before use by bubbling argon through the reaction mixture before 
addition of the hydrazine.  NMR spectra of 5-amino-1,10-phenanthroline (2) maintains the 
characteristic peaks of the 5-nitro-1,10-phenanthroline (1) while exhibiting a significant up-field 
shift as well as an additional N-H peak at δ 7.24 indicating successful ligand synthesis.  FTIR 
spectra displayed the disappearance of the NO2 stretching bands present in the starting material 
as well as the appearance of NH2 stretching bands.   
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3.1.2 ULTRAVIOLET-VISIBLE ABSORPTION/FLUORESCENT EMISSION STUDIES 
 
 
 
Scheme 14. Synthesis of Luminescent Lanthanide Complexes 
 
 Phenanthroline-lanthanide complexes were formed to obtain a luminescent profile of the 
proposed molecule.  Complexes explored include 1,10-phenanthroline - Eu(TTA)3 (4),  5-nitro-
1,10-phenanthroline - Eu(TTA)3 (5), and  5-amino-1,10-phenanthroline - Eu(TTA)3 (6).  
  It was necessary to perform this study to determine the viability of these ligands as components 
of our design.  Firstly EuCl3(H2O)6 and triflourothienyl acetone (TTA) were combined in 
aqueous NaOH to synthesize Eu(TTA)3(H2O)2 (3), collected as a white precipitant 
(31.2%)Error! Bookmark not defined.. Afterward synthesis of the phenanthroline-europium 
complexes involved stirring the appropriate ligand with Eu(TTA)3(H2O)2 (3) in a mixture of 
methanol and chloroform overnight.  The remaining solution was then filtered to yield the 
intended luminescent complex.    
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Figure 8. Lanthanide UV-Vis Complex Absorbance 
 
 
Figure 9. Lanthanide Complex Fluorescent Emission 
 
 Qualitative measurements for the complexes were made and quantum yields were not 
calculated.  Absorbance max in the UV-Vis appeared at ~340 nm for all of the observed 
complexes (Fig. 8).  Fluorescent spectra of the complexes showed the expected emission band at 
approximately ~615 nm for the europium ion (Fig. 9).  Fluorescence spectra indicated a Stoke’s 
shift of 275 nm while also displaying the narrow emission band of Eu3+. 
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3.2 POLYETHYLENE GLYCOL LINKER  
 
 
 
 
 
 
 
 
Scheme 15. Synthesis of the polyethylene glycol linker. Beginning with a reaction between 
tetraethylene glycol and t-butyl bromoacetate and concluding with the removal of the t-butyl 
groups in formic acid.   
 
3.2.1 SYNTHESIS AND CHARACTERIZATION 
 Synthesis of tert‐butyl 17‐hydroxy‐19,19‐dimethyl‐ 3,6,9,12,15,18‐hexaoxaicosanoate (7) 
was first attempted using a literature procedure that reacted bromoacetic acid and tetraethylene 
glycol under basic conditions (t-butoxide).  Repeated attempts failed to produce the desired 
product.   Synthesis was successfully accomplished through the addition of tetraethylene glycol 
and tert-butyl bromoacetate in a solution of dry tetrahydrofuran (THF) and sodium hydride 
(NaH)13 producing a yellow, viscous oil (Scheme 15).14  The reaction proved difficult to 
reproduce reliably often producing a mixture of half reacted side product.  Reaction yield 
appears to be very sensitive to moisture which is problematic since tetraethylene glycol is 
extremely hygroscopic.  Using the sodium hydride in excess caused the reaction to proceed in 
good yields (81.79%) and high purity.  It is believed that in addition to serving as a base, the 
7 
8 
84% 
99% 
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excess NaH also help dry the reaction mixture by reacting with any water that was present.  Pure 
product was obtained once before the hydroscopic nature of tetraethylene glycol began to create 
a mixed product, requiring chromatography to obtain the necessary purity.  NMR spectra 
displayed the characteristic 4 hydrogen singlet at δ3.94.  FTIR absorbance bands for the t-butyl 
ester were also diagnostic for monitoring the reaction.  Observed peaks include 2979, 2870, 
1747,1366, 1224, 1120, 945, 844, & 746 cm-1. 
   To remove the terminal t-butyl groups,  tert‐butyl 17‐hydroxy‐19,19‐dimethyl‐ 
3,6,9,12,15,18‐ hexaoxaicosanoate (7) was dissolved in formic acid, yielding 2‐hydroxy‐
1λ³,4,7,10,13,16‐ hexaoxaoctadec‐ 1‐yn‐18‐oic acid (8) as a yellow oil in high yield (99%)14 
(Scheme 15).  The reaction proceeded smoothly and quantitatively.  NMR spectra displayed a 
carboxylic acid peak at δ10.24, the diagnostic 4 hydrogen peak at δ4.16, and the removal of the 
terminal t-butyl groups. FTIR analysis of the diacid revealed the presence of the diagnostic peaks 
found in the starting material while also displaying the presence of a carboxylic acid –OH stretch 
at 3125 cm-1. 
 
3.2.4 GCMS & HPLC STUDIES 
 GCMS was performed to monitor reaction progress of the synthesis of tert‐butyl 17‐
hydroxy‐19,19‐dimethyl‐ 3,6,9,12,15,18‐hexaoxaicosanoate (7) and determine final purity. The 
reaction was characterized by the gradual disappearance of the starting material at retention time 
10.479 min and the appearance of the product peak at a retention time of 16.879 min. Purity was 
determined to be greater than 93% as demonstrated by area under the curve.  MS was highly 
fragmented due to the use of electron impact ionization, gas ionization would likely provide a 
less fragmented spectra.     
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 HPLC was performed to follow the synthesis of 2‐hydroxy‐1λ³,4,7,10,13,16‐ 
hexaoxaoctadec‐ 1‐yn‐18‐oic acid (8) and to determine resulting purity.  GC could not be used 
since the diacid did not move well on the GC column.  HPLC analysis displayed a purity of 
greater than 93% with a retention time of 2.449 min (mobile phase: 90% H2O/10% CH3CN).  
 
3.3 MELANOCYTE STIMULATING HORMONE (4) - PG 
 
 
 
 
 
 
 
 
Figure 10. Melanocyte Stimulating Hormone (4) - PG 
 
3.3.1 SOLID PHASE SYNTHESIS & CHARACTERIZATION 
 Microwave assisted solid phase peptide synthesis was performed using an adapted CEM 
Mars6 microwave with fiber optic probe.  The provided temperature probe was disassembled in 
order that the fiber optic probe could be placed directly into the reaction vessel, ensuring proper 
heating and allowing reactions to be completed in quick succession.  Synthesis was performed on 
a Rink amide resin, sequentially adding amino acids until completion of the targeted peptide 
chain. 10,15  Cleavage was performed on bench top due to the corrosive nature of TFA and the 
metal interior of the Mars6 microwave.  A sealed, non-reactive reaction vessel would be required 
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to complete microwave assisted cleavage.  Peptide was analyzed for molecular weight by LC-
MS with an M+1 mass spectral analysis within equipment error (Fig. 11).  Initial results 
displayed an observed purity greater than 70% with an M+1 peak of 781, indicating the presence 
of a major peptide product at the desired mass (Fig. 12).  
 
 
 
Figure 11. LCMS of MSH (4)-PG 
  
 
 
Figure 12. Mass Spectra of MSH (4)-PG 
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Due to the low retention time of the peptide in the LCMS chromatogram, additional HPLC was 
performed to confirm the previous results.  HPLC analysis revealed crude peptide purity as 
greater than 90% pure as demonstrated by area under the curve, confirming the presence of a 
major peptide product (Fig. 13). 
 
 
 
Figure 13. HPLC Chromatogram of MSH (4) - PG 
 
 3.4 CONCLUSION 
 Currently synthesis and characterization of the project’s three required components has 
been completed.  The functionalized phenanthroline ligand (2) was first synthesized from 1,10-
phenanthroline and characterized using NMR.  Ligand-lanthanide complexes (4,5,6) were 
subsequently synthesized and qualitatively analyzed via US-Vis/Fluorescent spectroscopy to 
determine their viability as a luminescent tags. Intense emission at ~615 nm after excitation at 
~340 nm qualitatively indicated a viable luminescent tag.  Following completion of the 
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functionalized ligand, a polyethylene glycol linker was synthesized from tetraethylene glycol and 
t-butyl bromoacetate (8).   NMR characterization and GCMS studies indicated successful linker 
synthesis.  Next a MSH(4)-PG peptide (10) was synthesized using a microwave assisted solid 
phase protocol. LCMS and HPLC analysis revealed a major peptide product with purity greater 
than 90% at the desired mass, indicating successful synthesis. The project’s conclusion involved 
the combination of the three individual components (2,8,10), which was first attempted by the 
addition of the modified polyethylene glycol linker (8) to the functionalized phenanthroline 
ligand (2) through the creation of an acid chloride intermediate (9). This reaction was determined 
to be unsuccessful after several attempts using various combinations of reaction conditions and 
solvent systems.   
 
3.5 FUTURE WORK 
 Additional work required to continue project synthesis includes: combination of the 
phenanthroline ligand and the polyethylene glycol linker, attachment of the linker-ligand 
molecule to the peptide on solid phase resin, cleavage and purification of the completed 
molecule, formation of the lanthanide chelate, and subsequent fluorescent studies.  
 Attempts to complete the final molecule proved difficult as various solubility issues 
prevented successful synthesis. This being mentioned, future attempts at synthesis of the 
proposed molecule must overcome solubility issues involved in the combination of the modified 
polyethylene glycol linker and the phenanthroline ligand.  Once this first combinatory step is 
accomplished, synthesis of the final molecule should follow without further difficulty.  
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Figure 14. 1H NMR spectrum of 5-Nitro-1,10-Phenanthroline in CDCl3 
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Figure 15. Zoomed 1H NMR spectrum of 5-Nitro-1,10-Phenanthroline in CDCl3 
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Figure 16. C13 NMR spectrum of 5-Nitro-1,10-Phenanthroline in CDCl3 
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Figure 17. FTIR spectrum of 5-Nitro-1,10-Phenanthroline. 
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Figure 18. 1H NMR spectrum of 5-Amine-1,10-Phenanthroline in DMSO. 
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     Figure 19. Zoomed 1H NMR spectrum of 5-Amine-1,10-Phenanthroline in DMSO. 
 
 
 
  
  
41 
 
 
 
Figure 20. C13 NMR spectrum of 5-Amine-1,10-Phenanthroline in DMSO. 
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Figure 21. FTIR spectrum of 5-Amine-1,10-Phenanthroline. 
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Figure 22. 1H NMR spectrum of tert‐butyl 17‐hydroxy‐19,19‐dimethyl‐ 3,6,9,12,15,18‐
hexaoxaicosanoate in CDCl3. 
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Figure 23. C13 NMR spectrum of tert‐butyl 17‐hydroxy‐19,19‐dimethyl‐ 3,6,9,12,15,18‐
hexaoxaicosanoate in CDCl3. 
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Figure 24. FTIR spectrum of tert‐butyl 17‐hydroxy‐19,19‐dimethyl‐ 3,6,9,12,15,18‐
hexaoxaicosanoate. 
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Figure 25. GCMS chromatogram of tert‐butyl 17‐hydroxy‐19,19‐dimethyl‐ 
3,6,9,12,15,18‐hexaoxaicosanoate. 
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 Figure 26. 1H NMR spectrum of 2‐hydroxy‐1λ³,4,7,10,13,16‐ hexaoxaoctadec‐ 1‐yn‐18‐oic 
acid in CDCl3. 
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Figure 27. C13 NMR spectrum of 2‐hydroxy‐1λ³,4,7,10,13,16‐ hexaoxaoctadec‐ 1‐yn‐18‐oic 
acid in CDCl3. 
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 Figure 28. FTIR spectrum of 2‐hydroxy‐1λ³,4,7,10,13,16‐ hexaoxaoctadec‐ 1‐yn‐18‐oic acid. 
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 Figure 29. HPLC chromatogram of 2‐hydroxy‐1λ³,4,7,10,13,16‐ hexaoxaoctadec‐ 1‐yn‐18‐oic     
acid. 
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Figure 30. FTIR spectrum of 2‐chloro‐1λ³,4,7,10,13,16‐hexaoxaoctadec‐1‐yn‐18‐oyl chloride. 
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 Figure 31. LC chromatogram of MSH(4)-PG 
 
 
 
 
 Figure 32. Mass spectra of MSH(4)-PG 
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Figure 33. HPLC chromatogram of MSH(4)-PG 
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APPENDIX A - PERMISSIONS 
 
 
 
Figure 2  
  
A G-Protein Coupled Receptor activating a cell’s signaling pathway through the presence of an 
agonist (signaling molecule) 
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